1204821-80-6Relevant articles and documents
BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS
-
Page/Page column 203, (2017/05/02)
Disclosed herein are compounds that are inhibitors of BDR4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BDR4 are also disclosed. In certain aspects, disclosed are compounds of Formula I through IV.
A class of 2,4-bisanilinopyrimidine Aurora A inhibitors with unusually high selectivity against Aurora B
Aliagas-Martin, Ignacio,Burdick, Dan,Corson, Laura,Dotson, Jennafer,Drummond, Jason,Fields, Carter,Huang, Oscar W.,Hunsaker, Thomas,Kleinheinz, Tracy,Krueger, Elaine,Liang, Jun,Moffat, John,Phillips, Gail,Pulk, Rebecca,Rawson, Thomas E.,Ultsch, Mark,Walker, Leslie,Wiesmann, Christian,Zhang, Birong,Zhu, Bing-Yan,Cochran, Andrea G.
experimental part, p. 3300 - 3307 (2010/03/24)
The two major Aurora kinases carry out critical functions at distinct mitotic stages. Selective inhibitors of these kinases, as well as pan-Aurora inhibitors, show antitumor efficacy and are now under clinical investigation. However, the ATP-binding sites